- Home
- RXST vs STRO Comparison
RXST vs STRO Comparison
Compare RXST & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RXST | STRO |
|---|---|---|
| Founded | 1997 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.6M | 181.4M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RXST | STRO |
|---|---|---|
| Price | $4.92 | $10.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 14 |
| Target Price | $7.57 | ★ $47.23 |
| AVG Volume (30 Days) | ★ 705.5K | 263.7K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $38,419,000.00 |
| Revenue This Year | $9.36 | N/A |
| Revenue Next Year | $1.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.40 | $0.72 |
| 52 Week High | $13.22 | $43.85 |
Technical Indicators
Market Signals| Indicator | RXST | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 47.30 | 27.70 |
| Support Level | $4.55 | $10.44 |
| Resistance Level | $4.98 | $16.99 |
| Average True Range (ATR) | 0.24 | 1.25 |
| MACD | 0.07 | -0.11 |
| Stochastic Oscillator | 77.34 | 9.07 |
Price Performance
Historical ComparisonAbout RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.